This clinical trial is focused on studying the effects of a medication called ulipristal acetate, which is available in the form of Esmya 5 mg tablets. The study is comparing this medication to standard surgical treatments for a condition known as uterine fibroids. Uterine fibroids are non-cancerous growths that develop in or on the uterus, often causing symptoms such as heavy menstrual bleeding, pain, and pressure in the pelvic area.
The purpose of the study is to evaluate how well ulipristal acetate improves the quality of life for women with symptomatic uterine fibroids compared to those who undergo surgery. Participants in the study will be randomly assigned to receive either the medication or a surgical treatment. The study will follow participants for a period of 24 months to assess changes in symptoms and overall quality of life. The study will also look at the costs associated with each treatment, including healthcare expenses and any impact on work productivity.
Throughout the study, researchers will monitor various aspects of health and well-being, such as pain levels, social participation, and sexual functioning. They will also track any changes in fibroid size, menstrual bleeding, and blood health, including liver function. The study aims to understand which treatment option is more effective and satisfactory for patients, as well as to identify any side effects or complications. The findings will help determine the best approach for managing uterine fibroids and improving patients’ lives.
The Netherlands 